准KRAS突变的NSCLC:新的技术知识和超越
David J Cantor1, Charu Aggarwal1,2,3
1Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
概括
具有KRAS突变的非小细胞肺癌 (NSCLC) 缺乏有效的向疗法. 过去的MEK抑制剂和化疗组合失败,需要针对这种常见的癌症亚型制定新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 突变KRAS的非小细胞肺癌 (NSCLC) 是NSCLC最常见的基因改变形式.
- 尽管患病率很高,但针对KRAS突变NSCLC的向治疗选择仍然有限.
- 之前的研究探讨了MEK抑制剂与化疗结合的结果,但没有取得成功.
研究的目的:
- 对KRAS突变NSCLC中MEK抑制剂和化疗组合的现有研究进行审查.
- 讨论这些先前治疗方法的局限性和失败.
- 探索和提出针对KRAS突变NSCLC的新策略.
主要方法:
- 关于KRAS突变NSCLC治疗的已发表研究的文献综述.
- 对MEK抑制剂和化疗组合的临床试验数据的分析.
- 讨论KRAS突变NSCLC的新兴治疗点和方法.
主要成果:
- 结合MEK抑制剂和化疗的多项研究没有证明治疗KRAS突变NSCLC的成功.
- 目前有针对性的治疗方法的局限性凸显了对创新治疗方式的需求.
- 该审查强调了有效准KRAS突变NSCLC的持续挑战.
结论:
- 针对KRAS突变NSCLC的向疗法是一个活跃的研究领域,有着未满足的需求.
- 超越MEK抑制剂/化疗组合的新方法对于改善患者的治疗结果至关重要.
- 进一步研究替代策略是有必要的,以应对这一重大临床挑战.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.0K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
560
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
560
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
